Harbright Ventures served as leading investor. Following the round, Robert Ross, Harbright’s founding partner, joined SonoVascular’s board of directors.
The Chapel Hill, North Carolina-based company develops the SonoThrombectomy system for treating venous thromboembolism (VTE). It designed the ultrasound-facilitated, thrombolytic-enhanced thrombectomy system to utilize microbubble-mediated cavitation as a core mechanism of action.
SonoVascular aims for its platform to treat blood clots more safely and effectively than today’s thrombectomy solutions. It provides a single-session, standalone, cath lab-based procedure. The company said SonoThrombectomy delivers maximum clot reduction with no blood loss or vascular trauma.
SonoVascular reports the successful treatment of 10 patients in South America as part of its first-in-human study for deep vein thrombosis (DVT). The company reports clot reduction in all cases. Follow-up at both 30 days and six months confirmed significant and sustained improvements from baseline.
With the funding, the company plans to support the achievement of two milestones in 2026. First, it hopes to secure FDA approval for a U.S.-based peripheral venous pivotal study. Then, it seeks to conduct a first-in-human study for the treatment of pulmonary embolism.
“SonoVascular has the rare combination of breakthrough technology and the experienced leadership necessary to redefine the standard of care in VTE,” said Robert Ross. “We led this round because SonoVascular is solving the ‘trade-off’ problem that has plagued DVT treatment for years – achieving total clot reduction without the typical risks of blood loss or vessel damage. With exceptionally strong FIH results, we believe this system is well-positioned to become the new standard of care. Equally important, SonoVascular’s solution will ease the burden on ICU capacity, saving hospitals and patients time and money.”
